Company news

CanSino Biologics, Inc. news in 2026

CanSino Biologics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

(688185)"Cansino Biologics Inc."Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for Conducting Clinical Trials of the Diphtheria, Tetanus and Acellular Pertussis (Five-Component) Combined Vaccine, Adsorbed, in a Population Aged 4–5 Years

November 16, 2026

(688185)"Cansino Biologics Inc."Announcement on Convening the Q3 2026 Performance Briefing

November 16, 2026

(688185)"Cansino Biologics Inc."Announcement on Change of Sponsor Representative for Continuous Supervision and Guidance

November 2, 2026

(688185)"Cansino Biologics Inc."Report for Q3 2026

October 27, 2026

(688185)"Cansino Biologics Inc."Announcement on Satisfaction of Vesting Conditions for the First Vesting Period of the Initial Grant under the 2025 A-Share Restricted Share Incentive Plan

October 27, 2026

(688185)"Cansino Biologics Inc."Announcement on Provision for Expected Credit Losses and Asset Impairment and Write-down of Certain Deferred Tax Assets for Q3 2026

October 27, 2026

(688185)"Cansino Biologics Inc."Announcement on Cancellation of Certain Granted but Unvested Restricted Shares

October 27, 2026

Announcement on Receipt of Government Subsidies

October 12, 2026

Announcement on Granting Certain Reserved Restricted Shares to Participants under the 2025 A-Share Restricted Share Incentive Plan

September 16, 2026

Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Biological Products and CXO Industry

September 4, 2026

Semi-annual Report for 2026

August 27, 2026

Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Performance Briefing

August 25, 2026

Announcement on Abnormal Fluctuations in Stock Trading

August 21, 2026

Announcement on Obtaining Drug Registration Certificate for Adsorbed Tetanus Vaccine

August 20, 2026

Announcement on Voluntary Disclosure of Acceptance of the Drug Registration Application for Adsorbed Tetanus, Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine (For Persons Aged 6 and Above)

August 16, 2026

CanSino Biologics: CanSinoBIO's Menhycia® Application Accepted by China's NMPA for Expanded Use in Population Aged 3 Months to 17 Years

July 19, 2026

CanSino Biologics: CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Expanding Global Reach

June 25, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

June 10, 2026

Announcement on Voluntary Disclosure of Initiating Phase I/II Clinical Trial and Completing 1st Subject Enrollment for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

May 25, 2026

Announcement on Changing Location of 2025 Annual General Meeting

May 19, 2026

Announcement on Voluntary Disclosure of Official Inclusion of the Adsorbed Acellular Pertussis (5-Component), Diphtheria and Tetanus Combined Vaccine (for People Aged 6 and Above) into the Priority Review List

May 11, 2026

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

April 30, 2026

Announcement on Amending the "Articles of Association" and Its Attachments and Formulating the "Remuneration Management System for Directors and Senior Management Members"

April 28, 2026

Announcement on Obtaining the Drug Registration Certificate for the Adsorbed Inactivated (Three-component) Diphtheria-Tetanus-Pertussis Vaccine for Infants and Young Children

April 12, 2026

Announcement on Requesting the General Meeting to Authorize the Board of Directors to Issue Shares to Specific Objects by Summary Procedure

March 30, 2026

Announcement on Voluntary Disclosure of Obtaining PIC/S GMP Certification

March 5, 2026

Announcement on Preliminary Earnings Estimate for 2025

February 26, 2026

Announcement on Obtaining the Supplementary Application Approval Notice for the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Carrier)

February 24, 2026

CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines

February 9, 2026

Announcement on Earnings Preannouncement for 2025

January 27, 2026

Announcement on Obtaining Notice of Approval for Drug Clinical Trial for 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197, TT)

January 5, 2026